MUSTANG BIO, INC. (MBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

-60K -40K -20K 0 20K 40K 60K Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 50K Q2 '18: 0 Q3 '18: 0 Q4 '18: -50K Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -17.1M Q4 '21: -20.1M Q1 '22: -19.6M Q2 '22: -18.2M Q3 '22: -18.8M Q4 '22: -19.4M Q1 '23: -16.3M Q2 '23: -13.9M Q3 '23: -10.3M Q4 '23: -8.7M Q1 '24: -5.2M Q2 '24: -8.5M Q3 '24: -1.5M Q4 '24: -1M Q1 '25: -253K Q2 '25: -885K Q3 '25: -624K Q4 '25: -670K Q1 '26: -1.1M Q2 '26: -1.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -17M Q4 '21: -20M Q1 '22: -19.8M Q2 '22: -19.1M Q3 '22: -19M Q4 '22: -19.6M Q1 '23: -16.7M Q2 '23: -16.2M Q3 '23: -10.1M Q4 '23: -8.6M Q1 '24: -5.2M Q2 '24: -8.2M Q3 '24: -1.4M Q4 '24: -952K Q1 '25: -153K Q2 '25: -762K Q3 '25: -468K Q4 '25: -538K Q1 '26: -955K Q2 '26: -1.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -11.3M Q4 '21: -14.7M Q1 '22: -16.3M Q2 '22: -17.6M Q3 '22: -15.9M Q4 '22: -15.3M Q1 '23: -17.8M Q2 '23: -12.4M Q3 '23: -12M Q4 '23: -7.3M Q1 '24: -5.3M Q2 '24: -2.3M Q3 '24: -1.8M Q4 '24: -2M Q1 '25: -1.4M Q2 '25: -1.3M Q3 '25: -818K Q4 '25: -1.7M Q1 '26: -1M Q2 '26: -967K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '19: -9.3M Q4 '19: -10.4M Q1 '20: -10.7M Q2 '20: -8.1M Q3 '20: -10.3M Q4 '20: -10.2M Q1 '21: -16M Q2 '21: -13.8M Q3 '21: -11.7M Q4 '21: -16.1M Q1 '22: -17.6M Q2 '22: -17.9M Q3 '22: -16.9M Q4 '22: -15.4M Q1 '23: -17.8M Q2 '23: -12.4M Q3 '23: -12M Q4 '23: -7.3M Q3 '24: -1.8M Q4 '24: -2M Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '21: 80.5M Q2 '21: 87.6M Q3 '21: 91.1M Q1 '22: 7.3M Q2 '22: 7.7M Q3 '22: 7.9M Q1 '23: 8.1M Q2 '23: 8.1M Q3 '23: 8.2M Q1 '24: 209.2K Q2 '24: 446.6K Q3 '24: 720.9K Q1 '25: 2.9M Q2 '25: 4M Q3 '25: 6.2M Q1 '26: 6.7M Q2 '26: 6.7M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-450.00 -300.00 -150.00 0.00 150.00 300.00 450.00 Q3 '21: -0.86 Q4 '21: -0.76 Q1 '22: -3.28 Q2 '22: -5.62 Q3 '22: -7.85 Q4 '22: -10.11 Q1 '23: -9.46 Q2 '23: -8.96 Q3 '23: -7.77 Q4 '23: -299.95 Q1 '24: -322.70 Q2 '24: -339.06 Q3 '24: -339.79 Q4 '24: -38.57 Q1 '25: -13.81 Q2 '25: 4.36 Q3 '25: 6.25 Q4 '25: -0.38 Q1 '26: -0.47 Q2 '26: -0.44 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.